ACELRX PHARMACEUT. DL-01 (R5XA) - Net Assets
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has net assets worth €17.04 Million EUR (≈ $19.92 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€29.72 Million ≈ $34.74 Million USD) and total liabilities (€12.68 Million ≈ $14.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check R5XA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €17.04 Million |
| % of Total Assets | 57.32% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 71.83 |
ACELRX PHARMACEUT. DL-01 - Net Assets Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's net assets have evolved over time, based on quarterly financial data. Also explore how large is ACELRX PHARMACEUT. DL-01's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual net assets of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. For live valuation and market cap data, see R5XA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €17.04 Million ≈ $19.92 Million |
+112.91% |
| 2024-12-31 | €8.00 Million ≈ $9.35 Million |
-43.28% |
| 2023-12-31 | €14.11 Million ≈ $16.49 Million |
-35.34% |
| 2022-12-31 | €21.81 Million ≈ $25.50 Million |
+160.78% |
| 2021-12-31 | €-35.89 Million ≈ $-41.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ACELRX PHARMACEUT. DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 206400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €488.56 Million | 2867.95% |
| Total Equity | €17.04 Million | 100.00% |
ACELRX PHARMACEUT. DL-01 Competitors by Market Cap
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Webus International Limited Ordinary Shares
NASDAQ:WETO
|
$38.93 Million |
|
Total Soft Bank Ltd
KQ:045340
|
$38.93 Million |
|
Wesizwe
JSE:WEZ
|
$38.93 Million |
|
Cokal Ltd
AU:CKA
|
$38.93 Million |
|
Skyline Builders Group Holding Limited Class A Ordinary Shares
NASDAQ:SKBL
|
$38.92 Million |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
$38.91 Million |
|
RS GROUP PLC
LSE:RS1
|
$38.91 Million |
|
GiG Software PLC
ST:GIG-SDB
|
$38.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACELRX PHARMACEUT. DL-01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,001,000 to 17,035,000, a change of 9,034,000 (112.9%).
- Net loss of 14,290,000 reduced equity.
- Other factors increased equity by 23,324,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-14.29 Million | -83.89% |
| Other Changes | €23.32 Million | +136.92% |
| Total Change | €- | 112.91% |
Book Value vs Market Value Analysis
This analysis compares ACELRX PHARMACEUT. DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.00x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-5.25 | €0.69 | x |
| 2022-12-31 | €2.65 | €0.69 | x |
| 2023-12-31 | €0.83 | €0.69 | x |
| 2024-12-31 | €0.47 | €0.69 | x |
| 2025-12-31 | €0.35 | €0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ACELRX PHARMACEUT. DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -83.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -51035.71%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.74x
- Recent ROE (-83.89%) is below the historical average (-31.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -1245.53% | 0.04x | 0.00x | €-31.51 Million |
| 2022 | 218.92% | 0.00% | 0.00x | 2.18x | €45.57 Million |
| 2023 | -130.43% | -2825.96% | 0.03x | 1.45x | €-19.81 Million |
| 2024 | -162.53% | 0.00% | 0.00x | 2.28x | €-13.80 Million |
| 2025 | -83.89% | -51035.71% | 0.00x | 1.74x | €-15.99 Million |
Industry Comparison
This section compares ACELRX PHARMACEUT. DL-01's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,047,785,316
- Average return on equity (ROE) among peers: -28.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACELRX PHARMACEUT. DL-01 (R5XA) | €17.04 Million | 0.00% | 0.74x | $38.92 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.22 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $20.26 Million | -37.64% | 0.19x | $13.93 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $81.13 Million |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more